MOR RESEARCH APPLICATIONS LTD.

The present disclosure relates to a system and methods for remote medical diagnosis and therapy and more particularly, for the patient driven diagnosis of vaginitis using multi sourced data.

There is provided a method of diagnosing a medical state associated with a neuro-psychiatric disorder in a subject, comprising: receiving EEG datasets from EEG electrodes monitoring a head of the subject, computing events for the EEG datasets, clustering the events into clusters, computing a p-adic representation of the clusters, extracting a p-adic topology from the p-adic representation of the clusters, computing a personal universal dendrogramic holographic signature (PUDHS) of the p-acid topology relative to a personalized threshold that separates between a relative large distance between events and a relatively small distance between events, the PUDHS denoting number of events below the personalized threshold, and diagnosing the medical state associated with the neuro-psychiatric disorder according to the PUDHS relative to a medical threshold that separates between presence of the medical state and non-presence of the medical state.

The present invention provides a composition based on cannabidiol (CBD) and chitosan for use in reducing blood cholesterol, blood LDL and blood triglycerides levels.

A system which can be used for carrying out a method for determining an efficacy of a transcranial magnetic stimulation (TMS) treatment, including: delivering TMS to a patient using a TMS protocol in a TMS treatment session; recording EEG signals before and after the delivering during the treatment session; recording EEG signals after completion of the treatment session; analyzing the recorded EEG signals to generate values of one or more EEG parameters; determining an acute effect and an intermediate effect of the TMS protocol on a brain state of the patient based on a change in values of the one or more EEG parameters; determining an efficacy of the TMS protocol based on the determined acute effect and the intermediate effect.

Methods and systems for predicting the onset and progression of neurodegenerative diseases using blood test data and machine learning models are disclosed. The method involves receiving blood test values for a target subject over a previous time period, extracting features from the blood test data, and applying a trained predictive model to compute a risk score indicating the probability of developing a neurodegenerative disease. The system includes a processor that executes code to perform the method and can be implemented as a standalone application, cloud-based service, or integrated with healthcare systems. The predictive models are trained using supervised learning on labeled data and can include statistical models or machine learning algorithms. The systems and methods enable early detection of neurodegenerative diseases, personalized risk prediction, and integration with existing healthcare infrastructure. By leveraging blood test data and machine learning techniques, patient outcomes may be improved.

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human transthyretin (TTR). The anti-TTR antibodies or antigen-binding fragments thereof are useful, for example, in detecting TTR and in treating TTR amyloidosis in a subject.

Disclosed herein is a multi-modal sensor system, including a wearable device configured to receive signals relating to a swallowing process of a subject, the wearable device including one or more surface Electromyograph sensors configured to receive signals relating to electrical potential in muscles of the throat, one or more bio-impedance sensors, one or more memories, one or more processors configured to operate one or more sensors of the wearable device, synchronize the signals to one or more predetermined events to generate a synchronization feature, receive the signals as a first diagnostic data set, analyze the first diagnostic data set, assess, based on the analysis, the swallowing process of the subject to yield an assessment output, and present the assessment output and determine a bio-impedance signal.

The use of mevalonolactone is provided for treating, preventing or alleviating diseases, disorders or conditions associated, directly or indirectly, with reduced mevalonic acid production in the mevalonate pathway, for example, due to damaged or hindered HMG CoA-reductase enzyme. Oral administration of mevalonolactone is provided for treating muscle cell and/or tissue damage caused at least in part due to impaired mevalonic acid production, as effected in diseases and disorders such as myopathy, statin-associated muscle symptom (SAMS), immune-mediated necrotizing myopathy (IMNM), rhabdomyolysis, muscular toxicity syndrome, myalgia, sarcopenia, and limb girdle muscular dystrophy (LGMD).

Disclosed is a device including at least 4 sections with a unique layout which includes a surface functionalized with an agent having specific binding affinity to a target molecule, and which allows flow. Disclosed are also a kit and a method for determining and quantifying the presence of a biomarker of a thyroid medical condition in a sample.

Using microstate data to evaluate Alzheimer's disease including dementia and/or mild cognitive impairment and/or depression and optionally provide treatment based on the diagnosis and/or modify treatment and/or diagnosis based on response to treatment, optionally as measured using microstate data. In one example, the method includes analyzing EEG data to generate one or more EEG parameter; and generating a risk for one or both of depression and MCI (mild cognitive impairment) based on said one or more EEG parameters. Optionally, the disease comprises MCI. Optionally, the disease comprises depression. Optionally, the one or more EEG parameter comprises a microstate-derived parameter. Optionally, the one or more EEG parameter comprises a microstate duration derived parameter.